Receptor-targeted iron oxide nanoparticles for molecular MR imaging of inflamed atherosclerotic plaques

Chuqiao Tu, Thomas S C Ng, Hargun K. Sohi, Heather A. Palko, Adrian House, Russell E. Jacobs, Angelique Y. Louie

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

In a number of literature reports iron oxide nanoparticles have been investigated for use in imaging atherosclerotic plaques and found to accumulate in plaques via uptake by macrophages, which are critical in the process of atheroma initiation, propagation, and rupture. However, the uptake of these agents is non-specific; thus the labeling efficiency for plaques in vivo is not ideal. We have developed targeted agents to improve the efficiency for labeling macrophage-laden plaques. These probes are based on iron oxide nanoparticles coated with dextran sulfate, a ligand of macrophage scavenger receptor type A (SR-A). We have sulfated dextran-coated iron oxide nanoparticles (DIO) with sulfur trioxide, thereby targeting our nanoparticle imaging agents to SR-A. The sulfated DIO (SDIO) remained mono-dispersed and had an average hydrodynamic diameter of 62 nm, an r 1 relaxivity of 18.1 mM -1 s -1, and an r 2 relaxivity of 95.8 mM -1 s -1 (37 °C, 1.4 T). Cell studies confirmed that these nanoparticles were nontoxic and specifically targeted to macrophages. In vivo MRI after intravenous injection of the contrast agent into an atherosclerotic mouse injury model showed substantial signal loss on the injured carotid at 4 and 24 h post-injection of SDIO. No discernable signal decrease was seen at the control carotid and only mild signal loss was observed for the injured carotid post-injection of non-sulfated DIO, indicating preferential uptake of the SDIO particles at the site of atherosclerotic plaque. These results indicate that SDIO can facilitate MRI detection and diagnosis of vulnerable plaques in atherosclerosis.

Original languageEnglish (US)
Pages (from-to)7209-7216
Number of pages8
JournalBiomaterials
Volume32
Issue number29
DOIs
StatePublished - Oct 2011

Fingerprint

Molecular Imaging
Atherosclerotic Plaques
Iron oxides
Nanoparticles
Dextran
Imaging techniques
Macrophages
Dextrans
Magnetic resonance imaging
Labeling
Scavenger Receptors
Dextran Sulfate
Injections
Hydrodynamics
ferric oxide
Intravenous Injections
Contrast Media
Rupture
Atherosclerosis
Sulfur

Keywords

  • Imaging agents
  • Inflammation
  • Macrophages
  • Molecular imaging
  • MRI (magnetic resonance imaging)
  • Nanoparticles

ASJC Scopus subject areas

  • Biomaterials
  • Bioengineering
  • Ceramics and Composites
  • Mechanics of Materials
  • Biophysics

Cite this

Tu, C., Ng, T. S. C., Sohi, H. K., Palko, H. A., House, A., Jacobs, R. E., & Louie, A. Y. (2011). Receptor-targeted iron oxide nanoparticles for molecular MR imaging of inflamed atherosclerotic plaques. Biomaterials, 32(29), 7209-7216. https://doi.org/10.1016/j.biomaterials.2011.06.026

Receptor-targeted iron oxide nanoparticles for molecular MR imaging of inflamed atherosclerotic plaques. / Tu, Chuqiao; Ng, Thomas S C; Sohi, Hargun K.; Palko, Heather A.; House, Adrian; Jacobs, Russell E.; Louie, Angelique Y.

In: Biomaterials, Vol. 32, No. 29, 10.2011, p. 7209-7216.

Research output: Contribution to journalArticle

Tu, C, Ng, TSC, Sohi, HK, Palko, HA, House, A, Jacobs, RE & Louie, AY 2011, 'Receptor-targeted iron oxide nanoparticles for molecular MR imaging of inflamed atherosclerotic plaques', Biomaterials, vol. 32, no. 29, pp. 7209-7216. https://doi.org/10.1016/j.biomaterials.2011.06.026
Tu, Chuqiao ; Ng, Thomas S C ; Sohi, Hargun K. ; Palko, Heather A. ; House, Adrian ; Jacobs, Russell E. ; Louie, Angelique Y. / Receptor-targeted iron oxide nanoparticles for molecular MR imaging of inflamed atherosclerotic plaques. In: Biomaterials. 2011 ; Vol. 32, No. 29. pp. 7209-7216.
@article{8ee9abb23f724cdfb7488484467d4129,
title = "Receptor-targeted iron oxide nanoparticles for molecular MR imaging of inflamed atherosclerotic plaques",
abstract = "In a number of literature reports iron oxide nanoparticles have been investigated for use in imaging atherosclerotic plaques and found to accumulate in plaques via uptake by macrophages, which are critical in the process of atheroma initiation, propagation, and rupture. However, the uptake of these agents is non-specific; thus the labeling efficiency for plaques in vivo is not ideal. We have developed targeted agents to improve the efficiency for labeling macrophage-laden plaques. These probes are based on iron oxide nanoparticles coated with dextran sulfate, a ligand of macrophage scavenger receptor type A (SR-A). We have sulfated dextran-coated iron oxide nanoparticles (DIO) with sulfur trioxide, thereby targeting our nanoparticle imaging agents to SR-A. The sulfated DIO (SDIO) remained mono-dispersed and had an average hydrodynamic diameter of 62 nm, an r 1 relaxivity of 18.1 mM -1 s -1, and an r 2 relaxivity of 95.8 mM -1 s -1 (37 °C, 1.4 T). Cell studies confirmed that these nanoparticles were nontoxic and specifically targeted to macrophages. In vivo MRI after intravenous injection of the contrast agent into an atherosclerotic mouse injury model showed substantial signal loss on the injured carotid at 4 and 24 h post-injection of SDIO. No discernable signal decrease was seen at the control carotid and only mild signal loss was observed for the injured carotid post-injection of non-sulfated DIO, indicating preferential uptake of the SDIO particles at the site of atherosclerotic plaque. These results indicate that SDIO can facilitate MRI detection and diagnosis of vulnerable plaques in atherosclerosis.",
keywords = "Imaging agents, Inflammation, Macrophages, Molecular imaging, MRI (magnetic resonance imaging), Nanoparticles",
author = "Chuqiao Tu and Ng, {Thomas S C} and Sohi, {Hargun K.} and Palko, {Heather A.} and Adrian House and Jacobs, {Russell E.} and Louie, {Angelique Y.}",
year = "2011",
month = "10",
doi = "10.1016/j.biomaterials.2011.06.026",
language = "English (US)",
volume = "32",
pages = "7209--7216",
journal = "Biomaterials",
issn = "0142-9612",
publisher = "Elsevier BV",
number = "29",

}

TY - JOUR

T1 - Receptor-targeted iron oxide nanoparticles for molecular MR imaging of inflamed atherosclerotic plaques

AU - Tu, Chuqiao

AU - Ng, Thomas S C

AU - Sohi, Hargun K.

AU - Palko, Heather A.

AU - House, Adrian

AU - Jacobs, Russell E.

AU - Louie, Angelique Y.

PY - 2011/10

Y1 - 2011/10

N2 - In a number of literature reports iron oxide nanoparticles have been investigated for use in imaging atherosclerotic plaques and found to accumulate in plaques via uptake by macrophages, which are critical in the process of atheroma initiation, propagation, and rupture. However, the uptake of these agents is non-specific; thus the labeling efficiency for plaques in vivo is not ideal. We have developed targeted agents to improve the efficiency for labeling macrophage-laden plaques. These probes are based on iron oxide nanoparticles coated with dextran sulfate, a ligand of macrophage scavenger receptor type A (SR-A). We have sulfated dextran-coated iron oxide nanoparticles (DIO) with sulfur trioxide, thereby targeting our nanoparticle imaging agents to SR-A. The sulfated DIO (SDIO) remained mono-dispersed and had an average hydrodynamic diameter of 62 nm, an r 1 relaxivity of 18.1 mM -1 s -1, and an r 2 relaxivity of 95.8 mM -1 s -1 (37 °C, 1.4 T). Cell studies confirmed that these nanoparticles were nontoxic and specifically targeted to macrophages. In vivo MRI after intravenous injection of the contrast agent into an atherosclerotic mouse injury model showed substantial signal loss on the injured carotid at 4 and 24 h post-injection of SDIO. No discernable signal decrease was seen at the control carotid and only mild signal loss was observed for the injured carotid post-injection of non-sulfated DIO, indicating preferential uptake of the SDIO particles at the site of atherosclerotic plaque. These results indicate that SDIO can facilitate MRI detection and diagnosis of vulnerable plaques in atherosclerosis.

AB - In a number of literature reports iron oxide nanoparticles have been investigated for use in imaging atherosclerotic plaques and found to accumulate in plaques via uptake by macrophages, which are critical in the process of atheroma initiation, propagation, and rupture. However, the uptake of these agents is non-specific; thus the labeling efficiency for plaques in vivo is not ideal. We have developed targeted agents to improve the efficiency for labeling macrophage-laden plaques. These probes are based on iron oxide nanoparticles coated with dextran sulfate, a ligand of macrophage scavenger receptor type A (SR-A). We have sulfated dextran-coated iron oxide nanoparticles (DIO) with sulfur trioxide, thereby targeting our nanoparticle imaging agents to SR-A. The sulfated DIO (SDIO) remained mono-dispersed and had an average hydrodynamic diameter of 62 nm, an r 1 relaxivity of 18.1 mM -1 s -1, and an r 2 relaxivity of 95.8 mM -1 s -1 (37 °C, 1.4 T). Cell studies confirmed that these nanoparticles were nontoxic and specifically targeted to macrophages. In vivo MRI after intravenous injection of the contrast agent into an atherosclerotic mouse injury model showed substantial signal loss on the injured carotid at 4 and 24 h post-injection of SDIO. No discernable signal decrease was seen at the control carotid and only mild signal loss was observed for the injured carotid post-injection of non-sulfated DIO, indicating preferential uptake of the SDIO particles at the site of atherosclerotic plaque. These results indicate that SDIO can facilitate MRI detection and diagnosis of vulnerable plaques in atherosclerosis.

KW - Imaging agents

KW - Inflammation

KW - Macrophages

KW - Molecular imaging

KW - MRI (magnetic resonance imaging)

KW - Nanoparticles

UR - http://www.scopus.com/inward/record.url?scp=79960842466&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960842466&partnerID=8YFLogxK

U2 - 10.1016/j.biomaterials.2011.06.026

DO - 10.1016/j.biomaterials.2011.06.026

M3 - Article

VL - 32

SP - 7209

EP - 7216

JO - Biomaterials

JF - Biomaterials

SN - 0142-9612

IS - 29

ER -